

Substance P can stimulate prostaglandin D₂ and leukotriene C₄ generation without granule exocytosis in murine mast cells

Khalil Karimi, Mirjam Kool, Frans P. Nijkamp, Frank A. Redegeld*

Department of Pharmacology and Pathophysiology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, P.O. Box 80.082, 3508 TB Utrecht, The Netherlands

Received 16 October 2003; received in revised form 26 February 2004; accepted 2 March 2004

Abstract

Mast cells play a central role in immediate type hypersensitivity and inflammatory events. Activation of mast cells not only can result in the release of preformed granule-associated mediators generally followed by de novo synthesis of lipid-derived substances. In the present study, we show that mast cell can be activated to release lipid mediators in absence of granule exocytosis. Primary cultured murine mast cells were stimulated with substance P and produced leukotriene C₄, and prostaglandin D₂ without the release of the granule-associated enzyme β-hexosaminidase. Indomethacin and nordihydroguaiaretic acid caused complete inhibition of arachidonic metabolite generation. Leukotriene C₄ and prostaglandin D₂ production was blocked by genistein, a specific inhibitor of tyrosine kinases, and bisindolylmaleimide, a protein kinase C inhibitor, indicating a role for both phosphorylation pathways in the substance P-stimulated lipid mediator production. We suggest that the cytokine microenvironment of the mast cell determines whether mast cell stimulation leads to only lipid mediator release or full activation. Analysis of granule-associated mediators only might underestimate the role of mast cell activation under (patho)physiological conditions.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Mast cell; Substance P; Neurogenic inflammation; Allergy; Exocytosis

1. Introduction

Mast cells are often found in close association with blood vessels and nerves, suggesting a role in the control of vascular permeability and in the induction of neurogenic inflammation. The neural network and mast cells form an interactive unit that is able to influence immune and inflammatory responses (Mori et al., 2002). Neuropeptides released from sensory neurons can induce mast cell activation and their mediators can further stimulate the release of neuropeptides from sensory nerves resulting in a bi-directional mast cell–sensory neuron autocatalytic loop (Ansel et al., 1993, 1996; Johnson and Erdos, 1973; Kowalski and Kaliner, 1988).

Activation of mast cells not only causes the release of preformed granule-associated mediators, but also initiates the de novo synthesis of lipid-derived substances (Metcalf et al., 1997). Large quantities of arachidonic acid are stored in membrane glycerolipids of mast cells. Upon cell activa-

tion, arachidonic acid is mobilized from the storage pools by different phospholipases and is converted to prostanoids and leukotrienes by cyclooxygenase and 5-lipoxygenase, respectively (Williams et al., 2000; Marone et al., 1997).

Morphologic and histochemical studies demonstrate the presence of multiple mast cell phenotypes within a single organism. Classically, rodent mast cells are categorized into two subtypes: connective tissue mast cells and mucosal mast cells (Galli, 1997). Both subtypes possibly represent the extreme phenotypes of a wide range of mast cell populations found in vivo and show differences in phenotype, expression of granule proteases, and their response to different stimuli. In contrast to freshly isolated peritoneal mast cells, bone marrow-derived mast cells (Levi-Schaffer and Shalit, 1989), which are generated in interleukin-3 containing medium and resemble immature mucosal mast cells, cannot be activated by substance P to release granule contents (Sakaguchi et al., 1992). On the other hand, primary cultured mast cells respond to cross-linking of the high affinity immunoglobulin (Ig) E receptor (FcεRI) or stimulation by cytokines like stem cell factor leading to degranulation and production of lipid mediators (Haisa et al., 1992; Mencia-Huerta et al., 1983;

* Corresponding author. Tel.: +31-30-2537358; fax: +31-30-2537420.
E-mail address: F.A.M.Redegeld@pharm.uu.nl (F.A. Redegeld).

Murakami et al., 1995a,b; Razin et al., 1982, 1983; Tkaczyk et al., 1996).

The signal transduction pathways leading to granule exocytosis and lipid mediator production has been suggested to operate through protein kinase C/ Ca^{2+} and mitogen-activated protein kinase pathway, respectively (Kawakami and Galli, 2002). Cross-linking of $\text{Fc}\epsilon\text{RI}$ results in activation of both pathways, but stimulation of mast cells by cationic compounds such as substance P and compound 48/80 does not always result in mast cell activation and degranulation (Ferry et al., 2002). The cytokine environment or chemical treatment of mast cells can alter this sensitivity to cationic compounds. For instance, quercetin-treated RBL-2H3 mast cells can be stimulated by compound 48/80 and substance P (Senyshyn et al., 1998; Swieter et al., 1993). In recent studies, it has been shown that bone marrow-derived mast cells cocultured with fibroblasts or with stem cell factor and interleukin-4 (Karimi et al., 1999; Ogasawara et al., 1997) gained responsiveness to substance P.

In this study, we provide evidence that bone marrow-derived mast cells do not show significant degranulation after stimulation with substance P, but do release lipid mediators prostaglandin D_2 and leukotriene C_4 . These results illustrate that the involvement of mast cells in neurogenic inflammation cannot be studied by monitoring the release of mast cell granule constituents only.

2. Materials and methods

The following were purchased: culture medium RPMI 1640, Tyrode's buffer powder, fetal calf serum, nonessential amino acids (GibcoBRL Life Technologies, Paisley, Scotland), penicillin–streptomycin, L-glutamine, sodium pyruvate, 2-mercaptoethanol, dinitrophenyl-conjugated human serum albumin (DNP–HSA), herbimycin, pertussis toxin, indomethacin, nordihydroguaiaretic acid (Sigma, St. Louis, MO, USA), nonidet P40 (BDH Laboratory Supplies, Poole, England), dinitrophenol (DNP)-specific IgE (H1DNPc26.82 hybridoma, kindly provided by J. Rivera, NIH, USA), albumin, fraction V and bisindolylmaleimide (Boehringer Mannheim, Germany), tissue-culture flasks (Costar, Cambridge, MA, USA), toluidine blue, HEPES (E. Merck, Darmstadt, Germany), genistein (Biomol. Res. Lab.), substance P (Novabiochem. Laufelfingen, Switzerland), leukotriene C_4 , prostaglandin D_2 assay kits (Amersham Life Science).

2.1. Mouse bone marrow cultures

Bone marrow cells from BALB/c mice (2×10^5 cells/ml) were cultured for three weeks in complete RPMI (RPMI 1640 medium containing 4 mmol/l L-glutamine, 5×10^{-5} mol/l 2-mercaptoethanol, 1 mmol/l sodium pyruvate, 100 U/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin, and 0.1 mmol/l nonessential amino acids) containing 10% vol/vol fetal calf serum in

presence 1 ng/ml of IL-3. After 3 weeks, the cells in the culture were identified as mast cells, as assessed by histochemical staining with toluidine blue.

2.2. Activation of bone marrow-derived mast cells with substance P

Bone marrow cells were cultured for three weeks to develop into mast cells. Bone marrow-derived mast cells were washed twice with Tyrode's buffer supplemented with 0.1% bovine serum albumin plus 10 mM HEPES and resuspended in this modified Tyrode's buffer at density of 0.6×10^6 cells/ml. A total of $2-3 \times 10^4$ cells were aliquoted in 96-well plates and activated with different concentrations of substance P (0–100 μM) for 30 min. Total release was established by adding nonidet P40 to get complete lysis of cells. After 1 h of incubation of aliquots with assay solution containing 4-methylumbelliferyl glucosaminide in 0.1 M citrate buffer (pH=4.5), the reaction was stopped by adding 0.2 M glycine buffer (pH=10.7). Fluorescence was measured using a multi-well plate reader at an emission wavelength $\lambda = 360$ nm and excitation wavelength $\lambda = 450$ nm. The percentage of degranulation was calculated as: $\{(a - b) / (t - b)\} \times 100$, where a is the amount of β -hexosaminidase released from stimulated cells, b is that released from unstimulated cells and t is total cellular content.

For comparison to IgE-dependent activation, mast cells were resuspended in culture medium (complete RPMI) and incubated with dinitrophenol-specific IgE for 1 h in 5% CO_2 at 37 °C (approximately 0.8×10^6 cells/ml). After sensitization with IgE, cells were washed twice with Tyrode's buffer supplemented with 0.1% bovine serum albumin and resuspended in the modified Tyrode's buffer at a density of 0.6×10^6 cells/ml. A total of $2-3 \times 10^4$ of cells were aliquoted in 96-well plates and activated with different concentrations of DNP–HSA (0–25 ng/ml) for 30 min.

In indicated experiments, the effect of indomethacin, nordihydroguaiaretic acid, genistein, and bisindolylmaleimide on prostaglandin D_2 and leukotriene C_4 production was assessed. Mast cells were incubated with indicated concentrations of the inhibitors or solvent only for 5–15 min and were activated as mentioned above with 100 μM of substance P.

2.3. Determination of prostaglandin D_2 and leukotriene C_4 production

Leukotriene C_4 and prostaglandin D_2 production was determined using a competition radioimmunoassay kit according to manufacturer's instruction (Amersham Life Science). Bone marrow-derived mast cells were primed with IgE supernatant following by activation with different concentration of dinitrophenyl-conjugated human serum albumin or stimulated with different concentrations of substance P as stated above. Supernatants were stored at -20 °C until further assay.

2.4. Presentation of data

All culture experiments were repeated two to three times with different bone marrow preparations pooled from three animals.

3. Results

3.1. Bone marrow-derived mast cell degranulate in response to cross-linking of IgE but not to substance P

After sensitization with dinitrophenol-specific IgE and challenge with multivalent Ag (DNP–HSA), interleukin-3 grown bone marrow-derived mast cells released β -hexosa-




Fig. 1. IgE-mediated and substance P-stimulated leukotriene C₄ and prostaglandin D₂ production from mouse bone marrow-derived mast cells. Mast cells labeled with IgE followed by activation with different concentrations of DNP–HSA (A) or stimulation with different concentrations of substance P (B) for 30 min. Leukotriene C₄ (closed symbol) and prostaglandin D₂ (open symbol) production was determined using a radioimmunoassay. The figure indicates representative experiment from four independent isolations (mean \pm S.E.M.).




Fig. 2. Determination of time course substance P and IgE/antigen-mediated leukotriene C₄ and prostaglandin D₂ production from mouse bone marrow-derived mast cells. Three weeks IL-3-dependent primary cultured mast cells from BALB/c mice were incubated with 100 μ M of substance P or 2.5 ng/ml antigen (DNP–HSA) (after sensitization with IgE) for 30 s to 30 min and subsequently leukotriene C₄ and prostaglandin D₂ production was assessed using a competition radioimmunoassay. Open circles represent Ag/IgE-induced PGD₂, closed circles SP-induced PGD₂, open triangles Ag/IgE-induced LTC₄, and closed triangles SP-induced LTC₄. Data are expressed as mean \pm S.D. of duplicate samples.

minidase. Cells released $40.3 \pm 1.5\%$ of their β -hexosaminidase content at 2.5 ng/ml DNP–HSA, while no substantial granule exocytosis was observed when the mast cells were treated with 100 μ M of substance P ($4.4 \pm 0.5\%$).

3.2. Leukotriene C₄ and prostaglandin D₂ generation in response to substance P

We measured the release of lipid mediators leukotriene C₄ and prostaglandin D₂ after cross-linking of IgE or stimulation with substance P. IgE/antigen-activated bone marrow-derived mast cells produced 27.4 ± 3.3 ng/10⁶ cells leukotriene C₄ and 3.0 ± 0.5 ng/10⁶ cells prostaglandin D₂ at 2.5 ng/ml DNP–HSA (Fig. 1A). Surprisingly, substance P (100 μ M) stimulated the cells to generate 13.4 ± 1.8 ng/10⁶ cells leukotriene C₄ and 1.5 ± 0.5 ng/10⁶ cells prostaglandin D₂ (Fig. 1B). Eicosanoid generation by substance P-stimulated mast cells was dose dependent. The cells produced 0.5 ± 0.1 , 1.3 ± 0.1 , 13.4 ± 1.7 and 16.3 ± 3.0 ng/ml of leukotriene C₄ in response to 10, 50, 100 and 200 μ M of substance P, respectively. The amounts of prostaglandin D₂ generation by substance P-stimulated mast cells were 0.2 ± 0.0 ng/ml at 50 μ M, 1.5 ± 0.5 ng/ml at 100 μ M and 2.5 ± 0.5 ng/ml at 200 μ M (Fig. 1B).

3.3. Time course of lipid generation by mast cells after substance P-initiated and IgE-mediated activation

Leukotriene C₄ and prostaglandin D₂ production was rapidly detected after activation with IgE/Ag (Fig. 2). It reached a maximum of 14.0 ± 8.7 ng leukotriene C₄ or 6.1 ± 1.5 ng prostaglandin D₂/10⁶ cells at 10 min. The release of leukotriene C₄ and prostaglandin D₂ from mast cells stimulated by 100 μ M of substance P was measurable within 30 s (Fig. 2). The generation of leukotriene C₄ reached near maximal at 10 min post activation (15 ng/

10^6 cells), while prostaglandin D_2 production was more gradual and maximum was reached at 30 min post activation ($8.4 \text{ ng}/10^6$ cells).

It has been shown earlier that nordihydroguaiaretic acid completely blocks the generation of leukotrienes and partially inhibits prostaglandin production from RBL-2H3 mast cells after IgE-or calcium ionophore-mediated activation. Also, indomethacin was reported to inhibit prostanoid generation via inhibition of the cyclooxygenase pathway (Andersson et al., 1983; Chakravarty, 1984; Obata et al., 1996). Indeed, we found that the substance P-induced production of the arachidonic acid metabolites could be inhibited with nordihydroguaiaretic acid and indomethacin. Substance P-induced PGD_2 production in presence of indomethacin was completely blocked ($0.0 \pm 0.0\%$ of control, $n=4$), while LTC_4 generation in presence nordihydroguaiaretic acid was reduced to $7.7 \pm 0.8\%$ of control ($n=4$).

3.4. Signal transduction pathways in substance P-initiated lipid generation

To investigate the role of protein tyrosine kinases in arachidonic metabolite production induced by substance P, bone marrow-derived mast cells were preincubated with genistein, a well-known tyrosine kinase inhibitor. Genistein ($1 \mu\text{M}$ to inhibit prostaglandin D_2 and $10 \mu\text{M}$ for leukotriene C_4 production) effectively inhibited substance P-induced leukotriene C_4 and prostaglandin D_2 production (Fig. 3), indicating that activity of protein tyrosine kinases was required for arachidonic metabolite generation. In addition also a protein kinase C inhibitor, bisindolylmaleimide ($2.5 \mu\text{M}$), greatly reduced the lipid generation by mast cells in response to substance P, as shown in Fig. 3.




Fig. 3. Inhibitory effect of inhibitors for protein kinase C (bisindolylmaleimide) and protein tyrosine kinase (genistein) on substance P-mediated leukotriene C_4 (open bar) and prostaglandin D_2 (shaded bar) production by mouse bone marrow-derived mast cells. Three-week-old IL-3-dependent primary cultured mast cells from BALB/c mice were incubated with vehicle, $2.5 \mu\text{M}$ bisindolylmaleimide or $10 \mu\text{M}$ genistein and subsequently stimulated with $100 \mu\text{M}$ substance P (SP). Leukotriene C_4 and prostaglandin D_2 production was assessed using a competition radioimmunoassay. Data are expressed as mean \pm S.D. of duplicate samples; *significantly different from control (no inhibitor added), $P < 0.05$.

4. Discussion

Release of mast cell mediators can be induced by a variety of stimuli including antigens cross-linking cell-surface-bound IgE or IgG $_1$, complement products, neuropeptides and many physical agents (Mecheri and David, 1997). The response of mast cells to the neuropeptide substance P is dependent on the subtype of mast cell. It has been reported that mucosal mast cells including bone marrow-derived mast cells are not responsive to substance P (Lawrence et al., 1987), while substance P activates rat brain, peritoneal and human skin mast cells, leading to rapid histamine release by granule exocytosis (Church et al., 1991; Jozaki et al., 1990; Mousli et al., 1989). However, in contrast to IgE/antigen-induced prostaglandin D_2 and leukotriene C_4 production, in these human mast cells, substance P caused minimal eicosanoid generation. This suggests a fundamental difference in the biochemical mechanisms of cell activation via the IgE-receptor and substance P. In previous studies, we demonstrated that interleukin-3-dependent bone marrow-derived mast cells treated with recombinant stem cell factor plus interleukin-4 gain functional responsiveness to substance P and can be activated by substance P to release β -hexosaminidase and to produce arachidonic acid metabolites (Karimi et al., 1999). In subsequent studies, we showed that stem cell factor and interleukin-4 induced an up-regulation of the neurokinin-1 receptor expression (Van der Kleij et al., 2003) and activation at low concentrations of substance P was neurokinin-1 receptor-dependent. At higher neuropeptide concentrations mast cells are activated through a receptor-independent mechanism (Van der Kleij et al., 2003). In our present study, we show that mouse mast cells derived from a culture of bone marrow cells with interleukin-3 do not respond to substance P by degranulation, but surprisingly generate prostaglandin D_2 and leukotriene C_4 (Fig. 1).

Murakami et al. showed that in contrast to the IgE-mediated production of arachidonic acid metabolites, culturing of murine bone marrow-derived mast cells with stem cell factor induced a progressive loss of their capacity to undergo IgE-mediated exocytosis. In addition, cytokine generation by human mast cells induced by cysteinyl leukotrienes and uridine diphosphate was shown without histamine release or prostaglandin D_2 generation (Mellor et al., 2002). In the RBL-2H3 mast cell line, at least two cascades are activated via the high affinity IgE receptor and the G protein-coupled muscarinic m1 receptor. Phospholipase C/protein kinase C are important for the regulation of granule secretion, while the mitogen activated protein kinase/phospholipase A_2 pathway accounts for arachidonic metabolite generation (Hirasawa et al., 1995a,b). In addition, it has been suggested that the basic secretagogue compound 48/80 stimulates rat peritoneal mast cells via two distinct signaling pathways, the first leading to exocytosis and release of preformed mediators such as histamine and the second pathway mediates the metabolism of arachidonic acid (Shefler et al., 1998). It was later demonstrated

that phospholipase- β and - γ are in control of mast cell stimulation by basic secretagogues leading to granule exocytosis and arachidonate release, respectively (Ferry et al., 2001). Taken together, these findings support a differential regulation of the respective signal transduction pathways leading to exocytosis and lipid mediator production in mast cells. Monitoring of degranulation (measured as release of granule mediators) may therefore not suffice as an adequate marker for mast cell activation.

The mechanism behind substance P-induced lipid mediator production remains to be further elucidated. In a recent study, we showed that stimulation of mast cells grown interleukin-3 with substance P is independent of the neurokinin-1 receptor (Van der Kleij et al., 2003) and likely through direct interaction with G proteins (Shefler et al., 1998; Ferry et al., 2001). Our study shows that substance P-induced lipid mediator production in mouse bone marrow-derived mast cells is completely blocked with a specific tyrosine kinase inhibitor, implicating activation of protein tyrosine phosphorylation in arachidonic acid metabolite production. Also, protein kinase C was shown to be important because pretreatment with bisindolylmaleimide greatly reduced the substance P-induced lipid generation (Fig. 3). These findings point to an involvement of protein phosphorylation by protein tyrosine kinase(s) and protein kinase C in the substance P-stimulated production of lipid mediators by mast cells. A role for these enzymes has been suggested earlier for stimulation of mast cells by basic secretagogues (Shefler and Sagi-Eisenberg, 2001; Ferry et al., 2001).

In neurogenic inflammation, actions of mast cells can be triggered by the release of transmitters from sensory nerves, mainly neuropeptides (Foreman and Jordan, 1983). Products of mast cells, including leukotrienes, have also been shown to evoke the release of substance P in the airways (Martins et al., 1991; Saria, 1988). Our study shows that mast cells do not necessarily release granule contents upon stimulation by neuropeptides, but can synthesize and release arachidonic acid metabolites. Indeed, these products can stimulate c-fibers and thereafter propagate and worsen a neurogenic inflammation. Our results further suggest that monitoring mast cell granule release in vivo only may underestimate the role of mast cells in these situations.

Acknowledgements

The authors thanks GlaxoWellcome, The Netherlands, and the Ferdowsi University, Iran, for their financial support for this study.

References

Andersson, R.G., Saldeen, K., Saldeen, T., 1983. A fibrin(ogen) derived pentapeptide induces vasodilation, prostacyclin release and an increase in cyclic AMP. *Thromb. Res.* 30, 213–218.

Ansel, J.C., Brown, J.R., Payan, D.G., Brown, M.A., 1993. Substance P

selectively activates TNF-alpha gene expression in murine mast cells. *J. Immunol.* 150, 4478–4485.

Ansel, J.C., Kaynard, A.H., Armstrong, C.A., Olerud, J., Bunnett, N., Payan, D., 1996. Skin–nervous system interactions. *J. Invest. Dermatol.* 106, 198–204.

Chakravarty, N., 1984. Effect of arachidonic acid metabolism on the release of histamine and SRS (leukotrienes) from guinea-pig lung. *Agents Actions* 14, 429–434.

Church, M.K., el-Lati, S., Caulfield, J.P., 1991. Neuropeptide-induced secretion from human skin mast cells. *Int. Arch. Allergy Appl. Immunol.* 94, 310–318.

Ferry, X., Eichwald, V., Daefler, L., Landry, Y., 2001. Activation of $\beta\gamma$ subunits of G_{12} and G_{13} proteins by basic secretagogues induce exocytosis through phospholipase C β and arachidonate release through phospholipase C γ in mast cells. *J. Immunol.* 167, 4805–4813.

Ferry, X., Brehin, S., Kamel, R., Landry, Y., 2002. G protein-dependent activation of mast cell by peptides and basic secretagogues. *Peptides* 23, 1507–1515.

Foreman, J., Jordan, C., 1983. Histamine release and vascular changes induced by neuropeptides. *Agents Actions* 13, 105–116.

Galli, S.J., 1997. The Paul Kallos Memorial Lecture. The mast cell: a versatile effector cell for a challenging world. *Int. Arch. Allergy Immunol.* 113, 14–22.

Haisa, S., Chang, H.S., Bewtra, A.K., Hiratani, M., Tamura, N., Bewtra, C., Townley, R.G., 1992. Long-term cultured mouse mast cells: ultrastructure, histamine and leukotriene levels. *Int. Arch. Allergy Immunol.* 98, 169–177.

Hirasawa, N., Santini, F., Beaven, M.A., 1995a. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. *J. Immunol.* 154, 5391–5402.

Hirasawa, N., Scharenberg, A., Yamamura, H., Beaven, M.A., Kinet, J.P., 1995b. A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc epsilon R1 is not shared by a G protein-coupled receptor. *J. Biol. Chem.* 270, 10960–10967.

Johnson, A.R., Erdos, E.G., 1973. Release of histamine from mast cells by vasoactive peptides. *Proc. Soc. Exp. Biol. Med.* 142, 1252–1256.

Jozaki, K., Kuriu, A., Waki, N., Adachi, S., Yamatodani, A., Tarui, S., Kitamura, Y., 1990. Proliferative potential of murine peritoneal mast cells after degranulation induced by compound 48/80, substance P, tetradecanoylphorbol acetate, or calcium ionophore A23187. *J. Immunol.* 145, 4252–4256.

Karimi, K., Redegeld, F.A., Heijdra, B., Nijkamp, F.P., 1999. Stem cell factor and interleukin-4 induce murine bone marrow cells to develop into mast cells with connective tissue type characteristics in vitro. *Exp. Hematol.* 27, 654–662.

Kawakami, T., Galli, S.J., 2002. Regulation of mast-cell and basophil function and survival by IgE. *Nat. Rev., Immunol.* 2, 773–786.

Kowalski, M.L., Kaliner, M.A., 1988. Neurogenic inflammation, vascular permeability, and mast cells. *J. Immunol.* 140, 3905–3911.

Lawrence, I.D., Warner, J.L., Cohan, V.L., Hubbard, W.C., Kagey-Sobotka, A., Lichtenstein, L.M., 1987. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. *J. Immunol.* 139, 3062–3069.

Levi-Schaffer, F., Shalit, M., 1989. Differential release of histamine and prostaglandin D₂ in rat peritoneal mast cells activated with peptides. *Int. Arch. Allergy Appl. Immunol.* 90, 352–357.

Marone, G., Casolaro, V., Patella, V., Florio, G., Triggiani, M., 1997. Molecular and cellular biology of mast cells and basophils. *Int. Arch. Allergy Immunol.* 114, 207–217.

Martins, M.A., Shore, S.A., Drazen, J.M., 1991. Peptidase modulation of the pulmonary effects of tachykinins. *Int. Arch. Allergy Appl. Immunol.* 94, 325–329.

Mecheri, S., David, B., 1997. Unravelling the mast cell dilemma: culprit or victim of its generosity? *Immunol. Today* 18, 212–215.

Mellor, E.A., Austen, K.F., Boyce, J.A., 2002. Cysteinyll leukotrienes and

- uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. *J. Exp. Med.* 195, 583–592.
- Mencia-Huerta, J.M., Razin, E., Ringel, E.W., Corey, E.J., Hoover, D., Austen, K.F., Lewis, R.A., 1983. Immunologic and ionophore-induced generation of leukotriene B₄ from mouse bone marrow-derived mast cells. *J. Immunol.* 130, 1885–1890.
- Metcalfé, D.D., Baram, D., Mekori, Y.A., 1997. Mast cells. *Physiol. Rev.* 77, 1033–1079.
- Mori, N., Suzuki, R., Furuno, T., McKay, D.M., Wada, M., Teshima, R., Bienenstock, J., Nakanishi, M., 2002. Nerve-mast cell (RBL) interaction: RBL membrane ruffling occurs at the contact site with an activated neurite. *Am. J. Physiol., Cell Physiol.* 283, C1738–C1744.
- Mousli, M., Bronner, C., Bueb, J.L., Tschirhart, E., Gies, J.P., Landry, Y., 1989. Activation of rat peritoneal mast cells by substance P and mastoparan. *J. Pharmacol. Exp. Ther.* 250, 329–335.
- Murakami, M., Austen, K.F., Arm, J.P., 1995a. The immediate phase of c-kit ligand stimulation of mouse bone marrow-derived mast cells elicits rapid leukotriene C₄ generation through posttranslational activation of cytosolic phospholipase A2 and 5-lipoxygenase. *J. Exp. Med.* 182, 197–206.
- Murakami, M., Matsumoto, R., Urade, Y., Austen, K.F., Arm, J.P., 1995b. c-Kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D₂ synthase and increased IgE-dependent prostaglandin D₂ generation in immature mouse mast cells. *J. Biol. Chem.* 270, 3239–3246.
- Obata, T., Nagakura, T., Kanbe, M., Masaki, T., Maekawa, K., Yamashita, K., 1996. IgE-anti-IgE-induced prostaglandin D₂ release from cultured human mast cells. *Biochem. Biophys. Res. Commun.* 225, 1015–1020.
- Ogasawara, T., Murakami, M., Suzukinishimura, T., Uchida, M.K., Kudo, I., 1997. Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand. *J. Immunol.* 158, 393–404.
- Razin, E., Mencia-Huerta, J.M., Lewis, R.A., Corey, E.J., Austen, K.F., 1982. Generation of leukotriene C₄ from a subclass of mast cells differentiated in vitro from mouse bone marrow. *Proc. Natl. Acad. Sci. U. S. A.* 79, 4665–4667.
- Razin, E., Mencia-Huerta, J.M., Stevens, R.L., Lewis, R.A., Liu, F.T., Corey, E., Austen, K.F., 1983. IgE-mediated release of leukotriene C₄, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. *J. Exp. Med.* 157, 189–201.
- Sakaguchi, N., Saito, H., Iikura, Y., 1992. The stimuli releasing histamine from murine bone marrow-derived mast cells (BMMC): 3. Effect of coculture with 3T3 fibroblasts on the histamine releasability of BMMC. *Arerugi* 41, 519–525.
- Saria, A., 1988. Neuroimmune interactions in the airways: implications for asthma, allergy, and other inflammatory airway diseases. *Brain Behav. Immun.* 2, 318–321.
- Senyshyn, J., Baumgartner, R.A., Beaven, M.A., 1998. Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway. *J. Immunol.* 160, 5136–5144.
- Shefler, I., Sagi-Eisenberg, R., 2001. G_i-Mediated activation of the syk kinase by receptor mimetic basic secretagogues of mast cells: role in mediating arachidonic acid/metabolites release. *J. Immunol.* 167, 475–481.
- Shefler, I., Taube, Z., Medalia, O., Sagi-Eisenberg, R., 1998. Basic secretagogues activate protein tyrosine phosphorylation and release of arachidonic acid in mast cells via a novel protein kinase C and phosphatidylinositol 3-kinase-dependent mechanism. *Eur. J. Immunol.* 28, 3468–3478.
- Swieter, M., Midura, R.J., Nishikata, H., Oliver, C., Berenstein, E.H., Mergenhagen, S.E., Hascall, V.C., Siraganian, R.P., 1993. Mouse 3T3 fibroblasts induce rat basophilic leukemia (RBL-2H3) cells to acquire responsiveness to compound 48/80. *J. Immunol.* 150, 617–624.
- Tkaczyk, C., Frandji, P., Botros, H.G., Poncet, P., Lapeyre, J., Peronet, R., David, B., Mecheri, S., 1996. Mouse bone marrow-derived mast cells and mast cell lines constitutively produce B cell growth and differentiation activities. *J. Immunol.* 157, 1720–1728.
- van der Kleij, H.P., Ma, D., Redegeld, F.A., Kraneveld, A.D., Nijkamp, F.P., Bienenstock, J., 2003. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. *J. Immunol.* 171, 2074–2079.
- Williams, C.S., Tsujii, M., Reese, J., Dey, S.K., DuBois, R.N., 2000. Host cyclooxygenase-2 modulates carcinoma growth. *J. Clin. Invest.* 105, 1589–1594.